Drugs, Investigational

• 

  Subject Areas on Research

  • A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. 
  • A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. 
  • A review of three-dimensional in vitro tissue models for drug discovery and transport studies. 
  • AZD6140. 
  • Aptamers: an emerging class of therapeutics. 
  • Bioelectronic medicines: a research roadmap. 
  • Clinical results in cachexia therapeutics. 
  • Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. 
  • Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. 
  • Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. 
  • Emerging drugs for attention-deficit/hyperactivity disorder. 
  • Emerging drugs for diabetic retinopathy. 
  • Emerging echinocandins for treatment of invasive fungal infections. 
  • Ethical issues in umbilical cord blood banking. Working Group on Ethical Issues in Umbilical Cord Blood Banking. 
  • Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. 
  • Extraordinary claims require extraordinary evidence. 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • Informed consent and investigational new drug abuses in the U.S. military. 
  • Inhibitors of platelet adhesion. 
  • Investigational dopamine antagonists for the treatment of schizophrenia. 
  • Investigational drugs in phase II clinical trials for acute coronary syndromes. 
  • Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. 
  • Lessons learned from a clinical trial. 
  • Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review. 
  • New FDA breakthrough-drug category--implications for patients. 
  • New antifungal agents. 
  • Novel medication targets for the treatment of alcoholism: preclinical studies. 
  • On power and sample size calculation for QT studies with recording replicates at given time point. 
  • Phase II cancer clinical trials with heterogeneous patient populations. 
  • Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. 
  • Prasugrel. 
  • Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials--Asian perspective. 
  • QT as a safety biomarker in drug development. 
  • Returns to R&D on new drug introductions in the 1980s. 
  • Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables. 
  • Statistical inference for cancer trials with treatment switching. 
  • Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience. 
  • Targeted therapy for thyroid cancer: An updated review of investigational agents. 
  • Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. 
  • The Food and Drug Administration and pragmatic clinical trials of marketed medical products. 
  • The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. 
  • The distribution of sales revenues from pharmaceutical innovation. 
  • The nonapproved use of medications. 
  • The price of innovation: new estimates of drug development costs. 
  • The quantity and quality of worldwide new drug introductions, 1982-2003. 
  • Update on the management of hyperuricemia and gout. 
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. 
  • Who should go first in trials with scarce agents? The views of potential participants. 
  • [Characteristics of hepatitis and influenza antivirals: update 2009].